follow up of Effects of Melatonin on Health-Related Quality of Life

The Effect of Melatonin on Increasing The Health-Related Quality of Life in Female Patients with Non-metastatic Breast Cancer: Three-year Follow up a Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221205056712N1

Enrollment

Registered

2023-03-15

Start date

2020-03-20

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Intervention 1: Intervention group: Oral Melatonin drug 6 mg (2 capsule of 3 mg) will be taken every night from 3 to 7 days before the start of the adjuvant treatment up to 3 years later. Intervention

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Breast Cancer Stages I, II, III According to Pathological Reports Patients at least 18 Years Old Have Signed a Written Consent Receiving Adjuvant Chemotherapy and Radiotherapy

Exclusion criteria

Exclusion criteria: Not signing a written consent Untreated Hypercalcemia Systolic Blood Pressure Less Than 100 mm Hg Warfarin Consumption Methylphenidate Consumption Consumption of sleep Pills During Melatonin Use TSH>5/5 or <0/5 Pregnancy or Breastfeeding

Design outcomes

Primary

Measure	Time frame
Quality of life. Timepoint: 3 years after last adjuvant treatment session. Method of measurement: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Sheida

Hamedan University of Medical Sciences

f.sheida@edu.umsha.ac.ir+98 81 3838 1076

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026